Index Entries

Shitiz Sriwastava, Kanika Sharma, Syed Hassan Khalid, Sakhi Bhansali, Ashish K. Shrestha, Mahmoud Elkhooly, Samiksha Srivastava, Erum Khan, Shruti Jaiswal, and Sijin Wen
March 18, 2022
Brain Sciences
West Virginia University

Background: With 10 vaccines approved by the WHO and nearly 48% of people fully vaccinated worldwide, we have observed several individual case studies of neurological manifestations post-COVID-19 vaccination. Through this systematic review, we aim to discern these CNS and PNS manifestations following the COVID-19 vaccine to help produce methods to mitigate them.

Methods: We conducted a thorough literature search of Google Scholar and PubMed from 1 December 2020 until 10 October 2021 and included all the case studies of COVID-19 vaccine-associated neurological side effects. The literature search and data analysis were performed by two independent reviewers according to prespecified inclusion and exclusion criteria using PRISMA.

Results: The most common CNS [central nervous system] manifestation was CVST (14.47%), found in females (64%) younger than 50 years (71%) after the first AstraZeneca dose (93%). Others included CNS demyelinating disorders (TM, ADEM, MS, NMOSD) (9.30%), encephalopathy/encephalitis (3.10%), and others (4.13%). The most common PNS manifestation was GBS (14.67%) found in males (71%) older than 50 years (79%), followed by Bell’s palsy (5.24%) and others (2.10%). Most occurred with the AstraZeneca (28.55%), Pfizer-BioNTech (9.18%), and Moderna (8.16%) vaccines. Nine (64%) out of the 14 patients with CVST died.

Key:

CVST - cerebral venous sinus thrombosis
TM – transverse myelitis
ADEM – acute disseminated encephalomyelitis
MS – multiple sclerosis
NMOSD - neuromyelitis optica spectrum disorder
PNS - peripheral nervous system
GBS - Guillain–Barré syndrome

document
adverse events,COVID-19,neurological disorders,vaccines